Nurix Therapeutics Inc
NASDAQ:NRIX
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
5.26
26.45
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Nurix Therapeutics Inc
Nurix Therapeutics Inc
Cash Equivalents
Nurix Therapeutics Inc
Cash Equivalents Peer Comparison
ABBV
GILD
AMGN
VRTX
REGN
Competitive Cash Equivalents Analysis
Latest Figures & CAGR of Competitors
| Company | Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Nurix Therapeutics Inc
NASDAQ:NRIX
|
Cash Equivalents
$54.6m
|
CAGR 3-Years
-23%
|
CAGR 5-Years
17%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Cash Equivalents
$13.1B
|
CAGR 3-Years
15%
|
CAGR 5-Years
20%
|
CAGR 10-Years
4%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Cash Equivalents
$2.8B
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-24%
|
CAGR 10-Years
-11%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Cash Equivalents
$9.3B
|
CAGR 3-Years
12%
|
CAGR 5-Years
11%
|
CAGR 10-Years
8%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Cash Equivalents
$4.6B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
7%
|
CAGR 10-Years
27%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Cash Equivalents
$1.9B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
13%
|
CAGR 10-Years
12%
|
See Also
What is Nurix Therapeutics Inc's Cash Equivalents?
Cash Equivalents
54.6m
USD
Based on the financial report for Nov 30, 2023, Nurix Therapeutics Inc's Cash Equivalents amounts to 54.6m USD.
What is Nurix Therapeutics Inc's Cash Equivalents growth rate?
Cash Equivalents CAGR 5Y
17%
Over the last year, the Cash Equivalents growth was -15%. The average annual Cash Equivalents growth rates for Nurix Therapeutics Inc have been -23% over the past three years , 17% over the past five years .
You don't have any saved screeners yet
